Brief: Vallon Pharmaceuticals And Gri Bio Enter Into Merger Agreement With Goal Of Advancing Innovative Pipeline Of Nkt Cell Regulators

GRI Bio

13/12/2022 21:40

Dec 13 (Reuters) - Vallon Pharmaceuticals Inc  VLON.O :
    * VALLON PHARMACEUTICALS AND GRI BIO ENTER INTO MERGER
AGREEMENT
WITH GOAL OF ADVANCING INNOVATIVE PIPELINE OF NKT CELL
REGULATORS
    * VALLON PHARMACEUTICALS AND GRI BIO ENTER INTO MERGER
AGREEMENT
WITH GOAL OF ADVANCING INNOVATIVE PIPELINE OF NKT CELL
REGULATORS
    * VALLON PHARMACEUTICALS INC - GRI BIO HAS COMMITTED CAPITAL
TO
FUND PLANNED OPERATIONS OF COMBINED COMPANY INTO MID-2024
    * VALLON PHARMACEUTICALS INC - GRI BIO HAS COMMITTED CAPITAL
TO
FUND PLANNED OPERATIONS OF COMBINED COMPANY INTO MID-2024
    * VALLON PHARMACEUTICALS INC - COMBINED COMPANY WILL OPERATE
AS
GRI BIO AND ADVANCE INNOVATIVE PIPELINE OF NATURAL KILLER T
(NKT) REGULATING THERAPIES
    * VALLON PHARMACEUTICALS INC - UNDER TERMS OF MERGER
AGREEMENT,
VALLON WILL ACQUIRE 100% OF OUTSTANDING EQUITY INTERESTS OF GRI
BIO
    * VALLON PHARMACEUTICALS- EQUITY HOLDERS OF GRI BIO EXPECTED
TO
OWN APPROXIMATELY 83% OF OUTSTANDING EQUITY OF COMBINED COMPANY
ON A FULLY DILUTED BASIS
    * VALLON PHARMACEUTICALS - COMBINED COMPANY WILL BE LED BY
MARC
HERTZ, GRI BIO'S CHIEF EXECUTIVE OFFICER, AND WILL BE
HEADQUARTERED IN LA JOLLA, CA
    * VALLON PHARMACEUTICALS INC - DAVID BAKER, CHIEF EXECUTIVE
OFFICER OF VALLON WILL BE JOINING BOARD OF DIRECTORS AS VALLON
DESIGNEE
    * VALLON PHARMACEUTICALS-  CO,GRI BIO ENTERED INTO DEAL
PURSUANT
TO WHICH GRI BIO TO MERGE WITH A WHOLLY-OWNED UNIT OF CO IN AN
ALL-STOCK TRANSACTION

Source text for Eikon:  ID:nGNXb02Qnr 
Further company coverage:  VLON.O 
 ((Reuters.Briefs@thomsonreuters.com;;))